https://www.selleckchem.com/pr....oducts/sovleplenib-h
Approximately 1 in 5 patients with breast cancer who undergo axillary lymph node dissection will develop lymphedema. To appropriately triage and monitor these patients for timely diagnosis and treatment, robust risk models are required. To evaluate the prognostic value of mammographic breast density in estimating lymphedema severity. This prognostic study collected data from July 16, 2018, to March 3, 2020, from the electronic health records of patients of the Cancer Rehabilitation and Survivorship Program at the Princess M
Like
Comment
Share
